Skip to main content
SpringerLink
Log in

HCC

  • Chapter
  • First Online:
Locoregional Tumor Therapy

  • 348 Accesses

Abstract

Hepatocellular carcinoma (HCC) ranks among the most common cancers worldwide, representing the sixth most common one, the third cause of cancer-related death, and accounts for 7% of all cancers [1]. HCC represents more than 90% of primary liver cancers and is a major global health problem. Over the last three decades, the age-adjusted incidence of liver cancer has risen to 4.6 per 100,000 individuals. The incidence of HCC will likely continue to rise as the hepatitis C epidemic reaches maturity and nonalcoholic steatohepatitis becomes more prevalent. The incidence of HCC increases progressively with advancing age in all populations, reaching a peak at 70 years [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 56.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. IARC. Globocan Estimated cancer Incidence, Mortality, Prevalence and Disability-adjusted life years (DALYs) Worldwide in 2008. 2011. http://www-dep.iarc.fr/. Accessed 1 Nov 11.

  2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–50.

    Article  CAS  PubMed  Google Scholar 

  3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2002;55:74–108.

    Article  Google Scholar 

  4. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006;43:1303–10.

    Article  PubMed  Google Scholar 

  5. Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009;50:923–8.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, Ikeda H, Shiina S, Kawabe T, Omata M. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–61.

    Article  PubMed  Google Scholar 

  7. Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, Chon CY, Choi EH, Han K-H. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885–94.

    Article  CAS  PubMed  Google Scholar 

  8. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.

    Article  CAS  PubMed  Google Scholar 

  9. Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lin CY, Lu SN. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer. 2007;120:2650–5.

    Article  CAS  PubMed  Google Scholar 

  10. Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol. 2016;8(17):703–15.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, Poulsen H, Tygstrup N. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology. 1984;4:430–5.

    Article  CAS  PubMed  Google Scholar 

  12. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6.

    Article  PubMed  Google Scholar 

  13. Ravaioli M, Grazi GL, Ballardini G, Cavrini G, Ercolani G, Cescon M, Zanello M, Cucchetti A, Tuci F, Del Gaudio M, Varotti G, Vetrone G, Trevisani F, Bolondi L, Pinna AD. Liver transplantation with the Meld system: a prospective study from a single European center. Am J Transpl. 2006;6:1572–7.

    Article  CAS  Google Scholar 

  14. Mayo End-Stage Liver Disease Score. www.mayoclinic.org/meld/mayomodel6.html. Accessed 20 Mar 2013.

  15. Freeman RB, Edwards EB. Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy. Liver Transpl. 2000;6:543–52.

    Article  PubMed  Google Scholar 

  16. Institute of Medicine. Analysis of waiting times. In: Organ Procurement and Transplantation: Current Policies and the Potential Impactof the DHHS Final Rule. Washington, DC: National Academy Press; 1999.

    Google Scholar 

  17. Organ Procurement and Transplantation Network-HRSA. Final rule with comment period. Fed Regist. 1998;63(63):16296–338.

    Google Scholar 

  18. Freeman RB, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, Merion R, Wolfe R, Turcotte J, Teperman L. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8:851–8.

    Article  PubMed  Google Scholar 

  19. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.

    Article  CAS  PubMed  Google Scholar 

  20. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D’Amico F, Ciarleglio FA, Bridda A, D’Amico DF. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44:723–31.

    Article  PubMed  Google Scholar 

  21. Wong R, Frenette C. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2011;7:16–24.

    Google Scholar 

  22. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.

    Article  PubMed  Google Scholar 

  23. Avunduk C, Eastwood GL. Manual of gastroenterology, diagnosis and therapy. 2nd ed. Boston, MA: Little Brown and Company; 1994. p. 415–7.

    Google Scholar 

  24. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL_EORT Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.

    Article  Google Scholar 

  25. Cucchetti A, Piscaglia F, Cescon M, Colecchia A, Ercolani G, Bolondi L, Pinna AD. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013;59(2):300–7.

    Article  PubMed  Google Scholar 

  26. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48(Suppl 1):S20–37.

    Article  CAS  PubMed  Google Scholar 

  27. Roayaie S, Blume IN, Thung SN, Guido M, Fiel M-I, Hiotis S, Labow DM, Llovet JM, Schwartz ME. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850–5.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Poon RTP, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg. 2002;236:602–11.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–54.

    Article  CAS  PubMed  Google Scholar 

  30. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N, Makuuchi M. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134:1908–16.

    Article  PubMed  Google Scholar 

  31. Margonis GA, Sasaki K, Andreatos N, Nishioka Y, Sugawara T, Amini N, Buettner S, Hashimoto M, Shindoh J, Pawlik TM. Prognostic impact of complications after resection of early stage hepatocellular carcinoma. Surg Oncol. 2017;15(7):791–804.

    Google Scholar 

  32. Shi M, Guo R-P, Lin X-J, Zhang Y-Q, Chen M-S, Zhang C-Q, Lau WY, Li J-Q. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007;245:36–43.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181–200.

    Article  PubMed  Google Scholar 

  34. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, Okita K, Omata M, Takayasu K, Yamaoka Y. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004;101:796–802.

    Article  PubMed  Google Scholar 

  35. Qi X, Liu L, Wang D, Li H, Su C, Guo X. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget. 2015;6(34):36838–59.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.

    Article  CAS  PubMed  Google Scholar 

  37. Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009;9(6):739–45.

    Article  CAS  PubMed  Google Scholar 

  38. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, et al. JSH Consensus-based clinical practice guidelines for the Management of Hepatocellular Carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014;3(3–4):458–68.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30:969–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224–9.

    Article  CAS  PubMed  Google Scholar 

  41. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461–9.

    Article  CAS  PubMed  Google Scholar 

  42. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.

    Article  CAS  PubMed  Google Scholar 

  44. Lo C-M, Ngan H, Tso W-K, Liu C-L, Lam C-M, Poon RT-P, Fan S-T, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.

    Article  CAS  PubMed  Google Scholar 

  45. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.

    Article  PubMed  Google Scholar 

  46. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995;332:1256–61.

    Article  Google Scholar 

  47. Yang HJ, Lee JH, Lee DH, et al. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology. 2014;271:909–18.

    Article  PubMed  Google Scholar 

  48. Kim HC. Role of C-arm cone-beam CT in chemoembolization for hepatocellular carcinoma. Korean J Radiol. 2015;16(1):114–24.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montañá X, Llovet JM, Bruix J. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–81.

    Article  CAS  PubMed  Google Scholar 

  50. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.

    Article  PubMed  Google Scholar 

  51. Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, Zheng S, Zhou L. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology. 2013;60(124):813–20.

    CAS  PubMed  Google Scholar 

  52. Han S, Zhang X, Zou L, Lu C, Zhang J, Li J, Li M. Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. PLoS One. 2014;9(8):e102686.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Laurent A, Wassef M, Chapot R, Houdart E, Merland J-J. Location of vessel occlusion of calibrated tris-acryl gelatin microspheres for tumor and arteriovenous malformation embolization. J Vasc Interv Radiol. 2004;15:491–6.

    Article  PubMed  Google Scholar 

  54. Dion JE, Rankin RN, Viñuela F, Fox AJ, Wallace AC, Mervart M. Dextran microsphere embolization: experimental and clinical experience with radiologic-pathologic correlation. Work in progress. Radiology. 1986;160:717–21.

    Article  CAS  PubMed  Google Scholar 

  55. Pillai KM, McKeever PE, Knutsen CA, Terrio PA, Prieskorn DM, Ensminger WD. Microscopic analysis of arterial microsphere distribution in rabbit liver and hepatic VX2 tumor. Sel Cancer Ther. 1991;7:39–48.

    Article  CAS  PubMed  Google Scholar 

  56. Yamamoto A, Imai S, Kobatake M, Yamashita T, Tamada T, Umetani K. Evaluation of tris-acryl gelatin microsphere embolization with monochromatic X rays: comparison with polyvinyl alcohol particles. J Vasc Interv Radiol. 2006;17:1797–802.

    Article  PubMed  Google Scholar 

  57. Bonomo G, Pedicini V, Monfardini L, Della Vigna P, Poretti D, Orgera G, Orsi F. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33:552–9.

    Article  PubMed  Google Scholar 

  58. Kluger MD, Halazun KJ, Barroso RT, Fox AN, Olsen SK, Madoff DC, Siegel AB, Weintraub JL, Sussman J, Brown RS Jr, Cherqui D, Emond JC. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transpl. 2014;20(5):536–43.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson KN, Garcia AR, Beattie C, Zhao B, Solomon SB, Schwartz LH, DeMatteo R, Abou-Alfa GK. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34(17):2046–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52–64.

    Article  CAS  PubMed  Google Scholar 

  61. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A, Nemcek AA, Gates VL, Abecassis M, Omary RA, Salem R. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71–81.

    Article  PubMed  Google Scholar 

  62. Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52:1741–9.

    Article  CAS  PubMed  Google Scholar 

  63. Sangro B, Bilbao JI, Iñarrairaegui M, Rodriguez M, Garrastachu P, Martinez-Cuesta A. Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres. Dig Dis. 2009;27:164–9.

    Article  PubMed  Google Scholar 

  64. Ludwig JM, Zhang D, Xing M, Kim HS. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. Eur Radiol. 2017;27(5):2031–41.

    Article  Google Scholar 

  65. Ku Y, Tominaga M, Iwasaki T, Fukumoto T, Muramatsu S, Kusunoki N, Sugimoto T, Suzuki Y, Kuroda Y, Saitoh Y. Efficacy of repeated percutaneous isolated liver chemoperfusion in local control of unresectable hepatocellular carcinoma. Hepatogastroenterology. 1998;45:1961–5.

    CAS  PubMed  Google Scholar 

  66. Gerunda GE, Neri D, Merenda R, Barbazza F, Zangrandi F, Meduri F, Bisello M, Valmasoni M, Gangemi A, Faccioli AM. Role of transarterial chemoembolization before liver resection for hepatocarcinoma. Liver Transpl. 2000;6:619–26.

    Article  CAS  PubMed  Google Scholar 

  67. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, Margreiter R, Vogel W. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003;9:557–63.

    Article  PubMed  Google Scholar 

  68. Yao FY, Hirose R, LaBerge JM, Davern TJ, Bass NM, Kerlan RK, Merriman R, Feng S, Freise CE, Ascher NL, Roberts JP. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 2005;11:1505–14.

    Article  PubMed  Google Scholar 

  69. Bharat A, Brown DB, Crippin JS, Gould JE, Lowell JA, Shenoy S, Desai NM, Chapman WC. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg. 2006;203:411–20.

    Article  PubMed  Google Scholar 

  70. Obed A, Beham A, Püllmann K, Becker H, Schlitt HJ, Lorf T. Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. World J Gastroenterol. 2007;13:761–7.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Zangos S, Eichler K, Balzer JO, Straub R, Hammerstingl R, Herzog C, Lehnert T, Heller M, Thalhammer A, Mack MG, Vogl TJ. Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT). Eur Radiol. 2007;17:553–63.

    Article  PubMed  Google Scholar 

  72. Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW, Jaeger D, Kalle C v, Schemmer P. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation—HeiLivCa [ISRCTN24081794]. BMC Cancer. 2008;8:349.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Zhou W-P, Lai ECH, Li A-J, Fu S-Y, Zhou J-P, Pan Z-Y, Lau WY, Wu M-C. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg. 2009;249:195–202.

    Article  PubMed  Google Scholar 

  74. Choi SB, Kim KS, Park YN, Choi JS, Lee WJ, Seong J, Han K-H, Lee JT. The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size. J Korean Med Sci. 2009;24:242–7.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Schaudt A, Kriener S, Schwarz W, Wullstein C, Zangos S, Vogl T, Mehrabi A, Fonouni H, Bechstein WO, Golling M. Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis. Clin Transpl. 2009;23(Suppl 21):61–7.

    Article  Google Scholar 

  76. Wang X, Li J, Peng Y, Dai Y, Xu W. Influence of preoperative transarterial chemoembolization on the prognosis for patients with resectable hepatocellular carcinoma: a meta-analysis of randomized trials. Hepatogastroenterology. 2011;58(107–108):869–74.

    PubMed  Google Scholar 

  77. Yu T, Xu X, Chen B. TACE combined with liver resection versus liver resection alone in the treatment of resectable HCC: a meta-analysis. Chinese German J Clin Oncol. 2013;12:P532–6.

    Article  Google Scholar 

  78. Si T, Chen Y, Ma D, Gong X, et al. Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials. Scand J Gastroenterol. 2016;51(12):1512–9.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg. 1998;133:183–8.

    Article  CAS  PubMed  Google Scholar 

  80. Ono T, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer. 2001;91:2378–85.

    Article  CAS  PubMed  Google Scholar 

  81. Wen J, Shen W-L, Yang S-H. Adjuvant hepatic chemotherapy after resection of solitary hepatocellular carcinoma associated with hepatitis B virus cirrhosis. Hepatobiliary Pancreat Dis Int. 2006;5:224–7.

    PubMed  Google Scholar 

  82. Li Q, Wang J, Sun Y, Cui YL, Juzi JT, Qian BY, Hao XS. Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases. Dig Surg. 2006;23:235–40.

    Article  CAS  PubMed  Google Scholar 

  83. Peng B-g, He Q, Li J-P, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 2009;198:313–8.

    Article  PubMed  Google Scholar 

  84. Zhong J-H, Li L-Q. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res. 2010;40:943–53.

    Article  CAS  PubMed  Google Scholar 

  85. Cheng X, Sun P, QG H, Song ZF, Xiong J, Zheng QC. Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta- analyses. J Cancer Res Clin Oncol. 2014;140:1159–70.

    Article  PubMed  Google Scholar 

  86. Furuse J, Ishii H, Satake M, Onaya H, Nose H, Mikami S, Sakai H, Mera K, Maru Y, Yoshino M. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am J Clin Oncol. 2003;26:159–64.

    Article  CAS  PubMed  Google Scholar 

  87. Huo T-I, Huang Y-H, Wu J-C, Chiang J-H, Lee P-C, Chang F-Y, Lee S-D. Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study. Ann Oncol. 2003;14:1648–53.

    Article  PubMed  Google Scholar 

  88. Dettmer A, Kirchhoff T-D, Gebel M, Zender L, Malek N-P, Panning B, Chavan A, Rosenthal H, Kubicka S, Krusche S, Merkesdal S, Galanski M, Manns M-P, Bleck J-S. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. World J Gastroenterol. 2006;12:3707–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Kirchhoff TD, Bleck JS, Dettmer A, Chavan A, Rosenthal H, Merkesdal S, Frericks B, Zender L, Malek NP, Greten TF, Kubicka S, Manns MP, Galanski M. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat Dis Int. 2007;6:259–66.

    CAS  PubMed  Google Scholar 

  90. Ishida K, Hirooka M, Hiraoka A, Kumagi T, Uehara T, Hiasa Y, Horiike N, Onji M. Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil. Jpn J Clin Oncol. 2008;38:596–603.

    Article  PubMed  Google Scholar 

  91. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116:1305–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Nagano H. Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology. 2010;78(Suppl 1):142–7.

    Article  CAS  PubMed  Google Scholar 

  93. Kucuk ON, Soydal C, Lacin S, Ozkan E, Bilgic S. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors. World J Surg Oncol. 2011;9:86.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Kondo M, Morimoto M, Numata K, Nozaki A, Tanaka K. Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Jpn J Clin Oncol. 2011;41:69–75.

    Article  PubMed  Google Scholar 

  95. Gao S, Zhang PJ, Guo JH, Chen H, HF X, et al. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. World J Gastroenterol. 2015;21(36):10443–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Ibrahim SM, Kulik L, Baker T, Ryu RK, Mulcahy MF, Abecassis M, Salem R, Lewandowski RJ. Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2012;35:1094–101.

    Article  PubMed  Google Scholar 

  97. Zhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis. Biosci Trends. 2015;9(5):289–98.

    Article  PubMed  Google Scholar 

  98. Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, et al. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2016;39(11):1580–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interventional Radiology Division, European Institute of Oncology, Milan, Italy

    Franco Orsi

Authors
  1. Franco Orsi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franco Orsi .

Editor information

Editors and Affiliations

  1. University Hospitals, Gasthuisberg and KU Leuven, Leuven, Belgium

    Eric Van Cutsem

  2. Department of Diagnostic Radiology, Johann Wolfgang Goethe University, Frankfurt, Germany

    Thomas J. Vogl

  3. Department of Interventional Radiology, European Institute of Oncology, Milano, Italy

    Franco Orsi

  4. IRCCS Ospedale San Martino IST, Genova, Italy

    Alberto Sobrero

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Orsi, F. (2018). HCC. In: Van Cutsem, E., Vogl, T., Orsi, F., Sobrero, A. (eds) Locoregional Tumor Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-69947-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-69947-9_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-69946-2

  • Online ISBN: 978-3-319-69947-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation